Eiger Bio Adds More Venture Capital Funds
Thursday, April 28, 2011 5:54:00 AM PDT | VentureDeal Staff
Palo Alto, California  --  Eiger Biopharmaceuticals has landed $3.55 million in additional venture capital funding, according to an SEC regulatory filing.

Eiger is focused on developing antiviral agents in the treatment of hepatitis.

Investors in the financing were not disclosed, nor was how the company intends to use the funding proceeds.

Eiger is still seeking an additional $1.45 million in funding.